oncology

Avastin market projected to grow from $7.82B in 2025 to $11.27B by 2030 at 7.5% CAGR, driven by cancer prevalence and biosimilar expansion.

Nuvectis Pharma will present three posters on NXP900, a first-in-class cancer inhibitor, at April's AACR Meeting in San Diego, highlighting combination and immunotherapy potential.

Moderna stock surges 70% in 2026 on vaccine and cancer therapy pipeline expansion, but $2.8B losses amid $1.9B revenue temper bullish sentiment.

Merck agrees to acquire Terns Pharmaceuticals for $6.7B to strengthen pipeline before Keytruda's 2028 patent expiry, but analysts suggest competing bids may emerge.

Nanobiotix denies acquisition speculation, stating no acquisition intent or assessment underway. Company cites factual inaccuracies in media reports.

Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.

Merck pursues $6B acquisition of Terns Pharma to strengthen oncology pipeline as Keytruda faces patent expiration amid broader $320B industry revenue cliff.

Aethlon Medical's Hemopurifier device advances to final clinical trial phase following positive safety review with no adverse events reported.

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Pfizer and UnitedHealth Group present buying opportunities for $500 investors. Pfizer trades at 9x forward earnings with oncology growth plans; UnitedHealth at 15x after cost-cutting initiatives.

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.

Pegasys market projected for growth via rising hepatitis B prevalence and indication expansion, though direct-acting antivirals and tariff pressures pose challenges. Asia-Pacific represents fastest-growing region.